Specifically, the membrane bound form of the cytokine was shown to sustain reparative processes via activation of type 2 TNF-α receptor (TNFR2) in oligodendrocytes [13], preventing the clinical use of TNF-α blockers in MS [47]. The gene discussed is TNF; the disease is myeloid sarcoma.